UCB agreed to acquire Neurona Therapeutics in a deal sized at up to about $1.15 billion, aiming to broaden its neurology pipeline around epilepsy. Neurona’s lead program, NRTX-1001, is being developed for epilepsy, and the acquisition reflects continued large-cap appetite for late-stage neuro assets and de-risked platforms—amid a steady flow of billion-dollar neuro transactions. Reporting also noted that the broader sector activity includes multiple high-value neuro deals in 2026 and that investor sentiment has been supported by both clinical signals and policy emphasis on mental health innovation. For UCB, the transaction adds a targeted epilepsy asset and provides near-term expansion capacity in a category where differentiation and clinical proof are increasingly decisive for valuation.